# Xycota Biosciences, BioAdaptives' Pending Acquisition, Launches Free PTSD Support Hub > Xycota Biosciences launched a free, zero-login PTSD resource hub for veterans and first responders, alongside its low-dose oral psilocybin research. - Published: 2026-11-11T19:54:32+00:00 - Section: Product Launches - Author: News Desk - URL: https://newsforagent.com/news/2026-11-11/xycota-ptsd-support-hub-launch - Source: [FinancialContent Business Page](https://www.financialcontent.com/article/accwirecq-2026-11-11-bioadaptives-acquisition-target-xycota-biosciences-launches-free-ptsd-tactical-and-support-hub-for-veterans-and-first-responders-alongside-at-home-psilocybin-research) ## Key takeaways - Xycota Biosciences launched a free PTSD Community & Resource Hub with no registration and no cloud personal health data collection. - The hub connects users to VA Vet Centers, The Headstrong Project, Cohen Veterans Network, Team Rubicon and Copline, plus the 988 Veterans Crisis Line. - BioAdaptives signed a definitive agreement on October 29, 2026 to acquire Xycota, a deal that has not closed. Xycota Biosciences, the pending acquisition target of BioAdaptives, launched a free PTSD Community & Resource Hub for veterans, active-duty service members, first responders and caregivers. [FinancialContent Business Page](https://www.financialcontent.com/article/accwirecq-2026-11-11-bioadaptives-acquisition-target-xycota-biosciences-launches-free-ptsd-tactical-and-support-hub-for-veterans-and-first-responders-alongside-at-home-psilocybin-research) published the announcement on November 11, 2026, during Veterans Day week. ## What The Xycota PTSD Hub Offers The hub at xycota.com/ptsd requires no login and collects no cloud personal health data, according to the announcement. It offers a 60-second physiological sigh pacer, a 4-4-4-4 box breathing timer and a 5-4-3-2-1 sensory reset for acute stress spikes. A resource matcher connects users to VA Vet Centers, The Headstrong Project, Cohen Veterans Network, Warrior Care Network / Home Base, Team Rubicon and Copline for law enforcement, plus immediate 988 Veterans Crisis Line access. A browser-only sleep and calm tracker can be exported for a personal physician, and shareable family field guides explain trauma physiology to spouses and families. The company said the hub is strictly educational and supportive, does not provide medical advice, and is separate from clinical-trial recruitment or enrollment. Lt. Col. Elton Johnson Jr. (Ret.), a 37-year U.S. Marine Corps Reserve and U.S. Army Reserve combat veteran and an incoming Xycota board designee, guided the project alongside Marvin S. Hausman, M.D., Xycota's co-founder and chief scientific officer and a former U.S. Public Health Service Surgeon at the National Institutes of Health. "Before our drug candidates ever reach a human trial, we wanted to put free, private, zero-red-tape tools directly into the hands of veterans, first responders, and their families today," said Brad Listermann, co-founder and chief executive officer of [Xycota Biosciences](https://akta.pro/company-profiles/00ypyem/xycota-biosciences). ## XYCO-02 And The At-Home Psilocybin Program Xycota's lead investigational candidate, XYCO-02, is a low-dose oral psilocybin capsule designed for potential at-home use below the threshold of noticeable psychedelic effects, targeting the BDNF/TrkB synaptic repair pathway. In a 2026 Neuropsychopharmacology study co-authored by Dr. Hausman, repeated low-dose oral psilocybin restored object-recognition memory in a genetic rat model of Fragile X syndrome; the benefit held when hallucination-linked serotonin receptors were blocked and vanished when TrkB was blocked. The study was conducted in rats, did not evaluate PTSD and has not been tested in humans. XYCO-01, a follow-on exosome-formulated psilocin program, targets frontotemporal dementia. "Chronic trauma leaves a measurable physical imprint on synaptic connections, not a character flaw," Hausman said. "Pairing immediate, accessible community education with a rigorous clinical test of whether sub-perceptual psilocybin can engage BDNF/TrkB repair signaling without hallucinations reflects who we are as a company." ## BioAdaptives' Supplement Business Behind The Deal [BioAdaptives](https://akta.pro/company-profiles/0009mqg/bioadaptives) markets human and animal dietary supplements and signed a definitive agreement on October 29, 2026 to acquire Xycota, a preclinical CNS biotechnology company. The transaction has not closed and remains subject to closing conditions detailed in a Form 8-K filed November 4, 2026. According to akta.pro [company records](https://akta.pro/company-data), BioAdaptives is a Las Vegas-based company founded in 2013 with a revenue estimate under $1 million and total funding of $5,000 from a 2013 pre-seed round. Its MyndSystem platform launched in May 2026 at $159.90 one-time or $119.93 via monthly subscription, and its MyndRenew nighttime formula received TruShield Certified status in June 2026. ## BioAdaptives' Earlier Product Rollouts BioAdaptives opened the commercial ordering window for its XcellaraHeart cellular wellness supplement on August 3, 2026, according to FinancialContent Business Page. The company commercially launched XcellaraHeart on August 12, 2026 at $159.95, backed by a clinical trial showing an average increase of 268.8% in circulating stem cells after four weeks, Stock Titan reported. On August 13, 2026, Yahoo reported that CEO James Keener voluntarily canceled and retired 43,250,000 shares of common stock to stabilize the company's equity structure after using them to address initial liquidity issues. ## Companies in this story - [Bioadaptives company profile](https://akta.pro/company-profiles/0009mqg/bioadaptives) · website: https://www.bioadaptives.com - [Xycota Biosciences company profile](https://akta.pro/company-profiles/00ypyem/xycota-biosciences) · website: https://xycota.com --- News for Agent · https://newsforagent.com/llms.txt